Latest Regulatory News

Green Critical Minerals Limited (ASX: GCM) has temporarily paused trading of its securities, signaling an impending announcement that investors should watch closely.

White Cliff Minerals has secured a crucial Class A Land Use Permit for its Rae Copper Project in Nunavut, setting the stage for maiden drilling activities to begin in March 2025. This regulatory milestone follows a positive environmental screening and signals progress in unlocking high-grade copper potential.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.

Latitude Group Holdings Limited has revised its distribution on Capital Notes from AUD 1.6136 to AUD 2.3052, reflecting a shift to a 0% franked component and the introduction of conduit foreign income.

Echelon Resources has agreed to acquire full ownership and operatorship of the EP145 exploration permit in the Northern Territory’s Amadeus Basin, aiming to unlock a discovered gas resource with modern technology.

Yandal Resources has reported promising air-core drilling results at its Caladan target area, revealing significant gold mineralisation and the emergence of a new prospect named Arrakis. Follow-up drilling is planned to further explore this early-stage discovery within the Yandal Greenstone Belt.

Cardno Limited has requested an immediate suspension from ASX quotation to facilitate its removal from the official ASX list, marking a significant step in its delisting process.

Benz Mining has completed its acquisition of the Glenburgh and Mt Egerton gold projects in Western Australia from Spartan Resources, marking a strategic expansion with Spartan becoming a significant shareholder and board participant.

Advance ZincTek reports steady profit before tax for H1 FY25, driven by strong North American growth and significant cost savings following its Perth facility closure.

First Graphene Limited has responded to an ASX price query, attributing its recent share price and volume surge to increased buying activity in Germany linked to prior commercial announcements, while reaffirming full compliance with ASX disclosure rules.

Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.

The Supreme Court of New South Wales has approved the scheme of arrangement for Southern Cross Gold Consolidated Ltd to acquire all remaining shares of Southern Cross Gold Ltd, setting the stage for a significant ownership consolidation and ASX trading changes.